EUVIMEDDescoperă EUVIMED
KorrekturOpen access

Correction to “Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort”

Obesity · 2026-06 · 34 (6) · 1354-1354

DOI: 10.1002/oby.70194 ↗

At a glance

Korrektur in Obesity, published online on 2026-03-22. The full text is freely available in PubMed Central.

RezumatDate bibliograficeCiteRelated studies

Abstract (original language)

Niciun rezumat disponibil.

Cite

APA

(2026). Correction to “Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort”. Obesity, 34(6), 1354-1354. https://doi.org/10.1002/oby.70194

Vancouver

Correction to “Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort”. Obesity. 2026;34(6):1354-1354. doi:10.1002/oby.70194

BibTeX
@article{euvimed2026,
  title = {Correction to “Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort”},
  journal = {Obesity},
  year = {2026},
  volume = {34},
  number = {6},
  pages = {1354--1354},
  doi = {10.1002/oby.70194}
}
Start for free →